| Description | Rimacalib is an inhibitor of Ca2+/calmodulin-dependent protein kinase II (IC50s: ~1 μM for CaMKIIα and ~30 μM for CaMKIIγ). |
| In vitro | Higher Fura-2 transient amplitude after the pause upon Rimacalib vs. 37.2±4.3% in control and in parallel cardiomyocyte contractility (135.0±15.4% vs. 97.2±16% increase of twitch amplitude, p=0.098). Rimacalib improves (by ~40%) Ca2+-transient potentiation during the 30 s stimulation pause [1]. |
| Target activity | CaMK IIγ:30 μM, CaMK IIα:1 μM |
| Synonyms | SMP 114 |
| molecular weight | 394.44 |
| Molecular formula | C22H23FN4O2 |
| CAS | 215174-50-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 125 mg/mL (316.90 mM), Sonication is recommended. |
| References | 1. Neef S, et al. Reduction of SR Ca2+ leak and arrhythmogenic cellular correlates by SMP-114, a novel CaMKII inhibitor with oral bioavailability. Basic Res Cardiol. 2017 Jul;112(4):45. |